Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 May-Jun:35:101764.
doi: 10.1016/j.tmaid.2020.101764. Epub 2020 May 30.

Hydroxychloroquine-azithromycin for COVID-19 - Warranted or dangerous?

Corneliu P Popescu  1 , Philip R Fischer  2
Affiliations
Editorial

Hydroxychloroquine-azithromycin for COVID-19 - Warranted or dangerous?

Corneliu P Popescu et al. Travel Med Infect Dis. 2020 May-Jun.
No abstract available

PubMed Disclaimer

Comment in

  • Real world and hyper reality.
    Gautret P, Million M, Raoult D. Gautret P, et al. Travel Med Infect Dis. 2021 Sep-Oct;43:102122. doi: 10.1016/j.tmaid.2021.102122. Epub 2021 Jun 16. Travel Med Infect Dis. 2021. PMID: 34144181 Free PMC article. No abstract available.

Comment on

  • Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France.
    Million M, Lagier JC, Gautret P, Colson P, Fournier PE, Amrane S, Hocquart M, Mailhe M, Esteves-Vieira V, Doudier B, Aubry C, Correard F, Giraud-Gatineau A, Roussel Y, Berenger C, Cassir N, Seng P, Zandotti C, Dhiver C, Ravaux I, Tomei C, Eldin C, Tissot-Dupont H, Honoré S, Stein A, Jacquier A, Deharo JC, Chabrière E, Levasseur A, Fenollar F, Rolain JM, Obadia Y, Brouqui P, Drancourt M, La Scola B, Parola P, Raoult D. Million M, et al. Travel Med Infect Dis. 2020 May-Jun;35:101738. doi: 10.1016/j.tmaid.2020.101738. Epub 2020 May 5. Travel Med Infect Dis. 2020. PMID: 32387409 Free PMC article.

References

    1. Vincent M.J., Bergeron E., Benjannet S. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69. doi: 10.1186/1743-422X-2-69. - DOI - PMC - PubMed
    1. Dyall J., Coleman C.M., Hart B.J., Venkataraman T., Holbrook M.R., Kindrachuk J. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014;58(8):4885–4893. doi: 10.1128/AAC.03036-14. - DOI - PMC - PubMed
    1. Million Matthieu, Lagier Jean-Christophe, Gautret Philippe, Colson Philippe, Fournier Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France. Trav Med Infect Dis. 2020 in press. - PMC - PubMed
    1. Docherty A.B., Harrison E.M., Green C.A., Hardwick H.E., Pius R., Norman L., Holden K.A., Read J.M., Dondelinger F., Carson G., Merson L., Lee J., Plotkin D., Sigfrid L., Halpin S., Jackson C., Gamble C., Horby P.W., Nguyen-Van-Tam J.S., Ho A., Russell C.D., Dunning J., Openshaw P.J., Baillie J.K., Semple M.G. ISARIC4C investigators. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020 May 22;369:m1985. doi: 10.1136/bmj.m1985. - DOI - PMC - PubMed
    1. Mehra M.R., Desai S.S., Ruschitzka F., Patel A.N. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020 May 22;S0140–6736(20) doi: 10.1016/S0140-6736(20)31180-6. 31180-6. - DOI - PMC - PubMed